glp-1 parkinson's disease The Emerging Role of RAs in GLP-1 Agonists: A New Frontier
Description
[DOI] [PubMed] [Google Scholar] 2.Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., Stein C., Basit A., Chan J.C.N., Mbanya J.C., et al
References Huang Y, Li Y, Pan H, Han L
Month 2 (Weeks 58): 0.5mg once weekly
Himeno et al
By activating both receptors, oxyntomodulin increases energy expenditure, reduces appetite, promotes weight loss, and improves glucose tolerance, showcasing the therapeutic potential of this dual mechanism [79]
